SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Minerva Neurosciences, Inc.
Date: Dec. 31, 2025 · CIK: 0001598646 · Accession: 0000000000-25-011919

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-292410

Date
December 31, 2025
Author
Division of
Form
UPLOAD
Company
Minerva Neurosciences, Inc.

Letter

Re: Minerva Neurosciences, Inc. Registration Statement on Form S-3 Filed December 23, 2025 File No. 333-292410 Dear Remy Luthringer:

December 31, 2025

Remy Luthringer Chief Executive Officer and Chairman of the Board of Directors Minerva Neurosciences, Inc. 1500 District Avenue Burlington, MA 01803

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ryan Sansom, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 December 31, 2025

Remy Luthringer
Chief Executive Officer and Chairman of the Board of Directors
Minerva Neurosciences, Inc.
1500 District Avenue
Burlington, MA 01803

 Re: Minerva Neurosciences, Inc.
 Registration Statement on Form S-3
 Filed December 23, 2025
 File No. 333-292410
Dear Remy Luthringer:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Daniel Crawford at 202-551-7767 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Ryan Sansom, Esq.
</TEXT>
</DOCUMENT>